Clinical trials: Hematological Patients
Hematological Malignancies
Dose-range Finding Treosulfan-based Conditioning
Evaluation of the safety and efficacy of 3 x 10, 3 x 12 or 3 x 14 g/m² Treosulfan resp., combined with 5 x 30 mg/m² fludarabine prior to allogeneic, hematopoietic stem cell transplantation of patients with hematological…
- Trial name
- NCT01063647
- Testing
- Treosulfan
- Where
- 7 sites in Finland, Germany and 2 more
- Volunteers
- 56 people
- Sponsor
- medac GmbH
Solid Tumors
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
- Trial name
- NCT00688116
- Testing
- STA 9090 (ganetespib)
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Synta Pharmaceuticals Corp.
Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma
Ceritinib Rare Indications Study in ALK+ Tumors
This is Proof-of-Concept (POC) study to assess the preliminary antitumor activity and safety and tolerablity using ceritinib (LDK378) in the treatment of life threatening tumors that are characterized by ALK genetic alteration…
- Conditions
- Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor, Glioblastoma
- Trial name
- NCT02465528
- Testing
- Ceritinib (LDK378)
- Where
- 14 sites in Czechia, Denmark and 6 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Hematological Malignancies
The Study of ICP-248 in Patients With Mature B-cell Malignancies
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study…
- Trial name
- NCT05728658
- Testing
- ICP-248, ICP-248+Orelabrutinib, ICP-248 +Rituximab
- Where
- 22 sites in China
- Volunteers
- 191 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Fatigue, Leukemia
Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent.
Several clinical trials have demonstrated the positive impact of physical functioning and fatigue in patients who received training programs during the myeloablative chemotherapy with stem cell transplantation.
- Conditions
- Fatigue, Leukemia, Lymphoma, Physical Disability
- Trial name
- NCT04406285
- Testing
- Standard protocol Leukemia, Periodic Resistance Training Program Leukemia, Standard protocol Lymphoma
- Where
- 2 sites in Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Cancer, Hematopoietic System--Cancer
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy.
- Conditions
- Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy
- Trial name
- NCT05164016
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Acute
Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study
The purpose of this study is to test the feasibility and acceptability of an adapted psychosocial intervention, called Emotion and Symptom-focused Engagement for Caregivers (EASE-CG), to reduce traumatic stress symptoms and other…
- Trial name
- EASE-CG (NCT05236296)
- Testing
- EASE-CG
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Ulcerative Colitis
Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis
Investigators aimed at investigating the prediction ability of faecal calprotectin to predict mucosal healing and histological remission in ulcerative colitis patients receiving biological therapy Investigators aimed to evaluate…
- Trial name
- NCT04818788
- Testing
- Biological Drug
- Volunteers
- 24 people
- Sponsor
- Assiut University
Myeloproliferative Disorders, Lymphoproliferative Disorders
In Vitro Drug Sensitivity Testing of Fresh Human Samples
Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid…
- Trial name
- ESAAC (NCT05001386)
- Testing
- Blood collection for the evaluation of the anti-drugs sensitivity
- Where
- 2 sites in France
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML)
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to…
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
- Trial name
- NCT06950034
- Testing
- STX-0712
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Solu Therapeutics, Inc
Hematologic Neoplasms, Burns
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies.
- Trial name
- NCT05549232
- Testing
- Hypoxic Red Blood Cells
- Where
- Norway
- Volunteers
- 22 people
- Sponsor
- Hemanext
Oncology, Periodontitis
PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications
The aim of this feasibility trial is to determine if it is safe and feasible to treat oral health diseases in people with haematological cancers before they start their chemotherapy to reduce complications and disruption to…
- Conditions
- Oncology, Periodontitis, Myeloma, Oral Mucositis
- Trial name
- NCT06450821
- Testing
- PRIOR [Proactive Intensive Oral Review & Treatment]
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Leeds
Health Care Quality, Health Care Evaluation
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.
- Trial name
- NCT01227356
- Testing
- imatinib and pegylated interferon
- Where
- 3 sites in Sweden
- Volunteers
- 112 people
- Sponsor
- Uppsala University
Peripheral Arterial Disease
Correlation Between Selected Haematological and Doppler Ultrasonic Parameters in Peripheral Arterial Diseased Patients
Forty patients of both sexes, aged between 50 and 60 years, were chosen from an outpatient vascular clinic in the El Sahel Education Hospital. Patients have been examined and referred to by a vascular specialist.
- Trial name
- NCT04830254
- Testing
- Transcutaneous Electrical Nerve Stimulation(TENS) device
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Hematological Malignancies
Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies
The purpose of this study is to evaluate the engraftment of donor hemopoiesis (proportion of transplanted patients with successful engraftment at day +42) in adult patients affected by high risk hematological malignancies after…
- Trial name
- IBCB (NCT00886522)
- Testing
- Intrabone cord blood infusion
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematologic Neoplasms
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
To reduce the number of donors treated with IV AMD3100 who require a second collection to obtain the minimum cells necessary for allogeneic stem cell transplant.
- Trial name
- NCT00914849
- Testing
- AMD3100, Leukopheresis, Stem cell transplant
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Washington University School of Medicine
Leukemia, Lymphoma
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
RATIONALE: Giving total-body irradiation and chemotherapy, such as cyclophosphamide, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells and helps stop the growth of…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00317785
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Neutropenia
The Utility of Multiplex PCR for Detection of DNA in Neutropenic Patients With Hematological Malignancies
Objectives: Invasive infections are the leading cause of morbidity and mortality in patients treated for hematological malignancies.
- Trial name
- MedIso (NCT01669005)
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bloodstream Infection, Gram Negative Infections
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients
The goal of this clinical trial is to learn if a personalized duration of antibiotic therapy, based on clinical stability, is as effective as a standard duration of at least 10 days in hospitalized patients with hematologic…
- Conditions
- Bloodstream Infection, Gram Negative Infections, Bacteraemia Caused by Gram-Negative Bacteria, Febrile Neutropenia (FN)
- Trial name
- PERaSTrA (NCT07372131)
- Testing
- Clinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration
- Where
- Italy
- Volunteers
- 172 people
- Sponsor
- Valeria Cento